TORONTO and HAIFA, Israel, Jan. 21, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (“NurExone” or the “Company”), a developer of exosome-based therapies for regenerative medicine, is pleased to announce that, subject to TSX Venture Exchange (“TSXV”) approval, it has closed a non-brokered private placement of 856,996 units (“Units”) at a price of C$0.56 per Unit for aggregate gross proceeds of C$479,917.76 (the “Offering”). The Company intends to use the proceeds of the Offering for working capital purposes.
In addition, the Company is pleased to announce that, further to its press release dated August 28, 2023 (the “August 28, 2023 Release”), the Company has received gross proceeds of C$727,755.04 through the exercise of 2,140,456 Class A Warrants at a price of C$0.34 per Class A Warrant issued in the first tranche of the non-brokered private placement of the Company which closed on August 25, 2023 (the “August 2023 Offering”). Capitalized terms not otherwise defined herein have the meanings attributed to them in the August 28, 2023 Release.